List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9134999/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment. Diabetes Technology and Therapeutics, 2022, 24, 18-25.	4.4	2
2	Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges. Diabetes Technology and Therapeutics, 2022, 24, 338-349.	4.4	2
3	Development of a Novel Insulin Sensor for Clinical Decision-Making. Journal of Diabetes Science and Technology, 2022, , 193229682110711.	2.2	3
4	Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 357-361.	4.4	7
5	Clinical Evaluation of a Novel Insulin Immunosensor. Journal of Diabetes Science and Technology, 2022, , 193229682210744.	2.2	3
6	Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm. Diabetes Technology and Therapeutics, 2022, 24, 471-480.	4.4	10
7	Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4. Diabetes Technology and Therapeutics, 2022, 24, 635-642.	4.4	8
8	Concept of the "Universal Slopeâ€! Toward Substantially Shorter Decentralized Insulin Immunoassays. Analytical Chemistry, 2022, 94, 9217-9225.	6.5	4
9	Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. Diabetes Technology and Therapeutics, 2021, 23, 245-252.	4.4	13
10	Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technology and Therapeutics, 2021, 23, 342-349.	4.4	58
11	A review of biomarkers in the context of type 1 diabetes: Biological sensing for enhanced glucose control. Bioengineering and Translational Medicine, 2021, 6, e10201.	7.1	33
12	Use of the Interoperable Artificial Pancreas System for Type 1 Diabetes Management During Psychological Stress. Journal of Diabetes Science and Technology, 2021, 15, 184-185.	2.2	5
13	Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology. Diabetes Technology and Therapeutics, 2021, 23, 120-127.	4.4	89
14	Predictive Low-Glucose Suspend Necessitates Less Carbohydrate Supplementation to Rescue Hypoglycemia: Need to Revisit Current Hypoglycemia Treatment Guidelines. Diabetes Technology and Therapeutics, 2021, 23, 512-516.	4.4	12
15	Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control. Diabetes Technology and Therapeutics, 2021, 23, 401-409.	4.4	27
16	Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. Diabetes Technology and Therapeutics, 2021, 23, 673-683.	4.4	30
17	Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care, 2021, 44, 1630-1640.	8.6	133
18	A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes. Diabetes Technology and Therapeutics, 2021, 23, 467-470.	4.4	11

#	Article	IF	CITATIONS
19	Clinical Experience of Continuous Glucose Monitoring in Pregnancy. Journal of Diabetes Science and Technology, 2021, 15, 193229682110246.	2.2	1
20	Activity detection and classification from wristband accelerometer data collected on people with type 1 diabetes in free-living conditions. Computers in Biology and Medicine, 2021, 135, 104633.	7.0	10
21	Longitudinal Observation of Insulin Use and Glucose Sensor Metrics in Pregnant Women with Type 1 Diabetes Using Continuous Glucose Monitors and Insulin Pumps: The LOIS-P Study. Diabetes Technology and Therapeutics, 2021, 23, 807-817.	4.4	18
22	Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations. Current Opinion in Biomedical Engineering, 2021, 19, 100312.	3.4	19
23	Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2020, 43, 1822-1828.	8.6	34
24	Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update. Endocrine Practice, 2020, 26, 714-721.	2.1	14
25	Decision Support Systems and Closed Loop. Diabetes Technology and Therapeutics, 2020, 22, S-47-S-62.	4.4	2
26	Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care, 2020, 43, 607-615.	8.6	40
27	63-OR: Towards Point-of-Care Devices: First Evaluation of an Insulin Immunosensor for Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	1
28	101-LB: Eighteen-Month Use of Closed-Loop Control (CLC): A Randomized, Controlled Trial. Diabetes, 2020, 69, 101-LB.	0.6	2
29	Randomized Crossover Comparison of Automated Insulin Delivery Versus Conventional Therapy Using an Unlocked Smartphone with Scheduled Pasta and Rice Meal Challenges in the Outpatient Setting. Diabetes Technology and Therapeutics, 2020, 22, 865-874.	4.4	8
30	The Effect of Two Types of Pasta Versus White Rice on Postprandial Blood Glucose Levels in Adults with Type 1 Diabetes: A Randomized Crossover Trial. Diabetes Technology and Therapeutics, 2019, 21, 485-492.	4.4	20
31	Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 1707-1717.	27.0	643
32	Decision Support Systems and Closed Loop. Diabetes Technology and Therapeutics, 2019, 21, S-42-S-56.	4.4	10
33	Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development. Diabetes Technology and Therapeutics, 2019, 21, 35-43.	4.4	42
34	The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. Diabetes Technology and Therapeutics, 2019, 21, 73-80.	4.4	13
35	Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technology and Therapeutics, 2018, 20, 257-262.	4.4	62
36	Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas. Journal of Diabetes Science and Technology, 2018, 12, 599-607.	2.2	21

#	Article	IF	CITATIONS
37	Closing the Loop. Diabetes Technology and Therapeutics, 2018, 20, S-41-S-54.	4.4	4
38	Body Mass Index Effect on Differing Responses to Psychological Stress in Blood Glucose Dynamics in Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2018, 12, 657-664.	2.2	5
39	Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes. Current Diabetes Reports, 2018, 18, 88.	4.2	26
40	Evaluation of an Artificial Pancreas with Enhanced Model Predictive Control and a Glucose Prediction Trust Index with Unannounced Exercise. Diabetes Technology and Therapeutics, 2018, 20, 455-464.	4.4	34
41	Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care, 2018, 41, 2155-2161.	8.6	184
42	Response to Comment on Pinsker et al. Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas. Diabetes Care 2016;39:1135–1142. Diabetes Care, 2017, 40, e4-e5.	8.6	22
43	Predictive Low-Glucose Suspend to Prevent Hypoglycemia. Diabetes Technology and Therapeutics, 2017, 19, 271-276.	4.4	7
44	Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. Diabetes Technology and Therapeutics, 2017, 19, 331-339.	4.4	56
45	Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Diabetes Care, 2017, 40, 1096-1102.	8.6	46
46	Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery. Diabetes Technology and Therapeutics, 2017, 19, 18-24.	4.4	120
47	Perspectives on Long-Distance Air Travel with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 744-748.	4.4	12
48	Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia. Diabetes Care, 2017, 40, 1719-1726.	8.6	68
49	A Personalized Week-to-Week Updating Algorithm to Improve Continuous Glucose Monitoring Performance. Journal of Diabetes Science and Technology, 2017, 11, 1070-1079.	2.2	6
50	Automated Bone Age Analysis with Lossy Image Files. Military Medicine, 2017, 182, e1769-e1772.	0.8	9
51	Techniques for Exercise Preparation and Management in Adults with Type 1 Diabetes. Canadian Journal of Diabetes, 2016, 40, 503-508.	0.8	48
52	Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care, 2016, 39, 1143-1150.	8.6	95
53	Minority groups and the artificial pancreas: who is (not) in line?. Lancet Diabetes and Endocrinology,the, 2016, 4, 880-881.	11.4	10
54	Enhanced Model Predictive Control (eMPC) Strategy for Automated Glucose Control. Industrial & Engineering Chemistry Research, 2016, 55, 11857-11868.	3.7	40

#	Article	IF	CITATIONS
55	Vitamin D deficiency versus non-accidental trauma: comment on "Rickets or abuse? A histologic comparison of rickets and child abuse-related fractures― Forensic Science, Medicine, and Pathology, 2016, 12, 119-120.	1.4	4
56	Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas. Diabetes Care, 2016, 39, 1135-1142.	8.6	123
57	Is Psychological Stress a Factor for Incorporation Into Future Closed-Loop Systems?. Journal of Diabetes Science and Technology, 2016, 10, 640-646.	2.2	21
58	Challenges Associated With Exercise Studies in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 993-994.	2.2	2
59	On the Use of Consumer-Grade Activity Monitoring Devices to Improve Predictions of Glycemic Variability. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2016, , 166-178.	0.3	1
60	Diabetes and â€~The Happiest Place on Earth': safely attending an amusement park and riding roller coasters. Practical Diabetes, 2015, 32, 329-331.	0.3	1
61	Empirical dynamic model identification for blood-glucose dynamics in response to physical activity. , 2015, 2015, 3834-3839.		6
62	Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?. Diabetes Technology and Therapeutics, 2015, 17, 311-315.	4.4	42
63	Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3878-3886.	3.6	67
64	Case 1: Hepatomegaly and Growth Failure in an 11-year-old Girl With Type 1 Diabetes. Pediatrics in Review, 2015, 36, 459-461.	0.4	1
65	Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <i>Standards of Medical Care in Diabetes—2015</i> . Diabetes Care 2015;38(Suppl. 1):S41–S48. Diabetes Care, 2015, 38, e174-e174.	8.6	43
66	Early Detection of Physical Activity for People With Type 1 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2015, 9, 1236-1245.	2.2	35
67	Hemichorea-Hemiballism Secondary to Non-Ketotic Hyperglycemia. Journal of Clinical Medicine Research, 2015, 7, 729-730.	1.2	11
68	False-Negative Sweat Chloride Testing in a Child With Cystic Fibrosis and Undiagnosed Hypohidrotic Ectodermal Dysplasia. Clinical Pediatrics, 2014, 53, 1203-1205.	0.8	1
69	Occult pyogenic liver abscess in an adolescent with type 2 diabetes. Endocrine, 2014, 45, 335-336.	2.3	8
70	Visual Diagnosis: 6-Month-Old Boy With Leg Pain. Pediatrics in Review, 2014, 35, e57-e60.	0.4	0
71	Primary hypothyroidism with growth failure and pituitary pseudotumor in a 13-year-old female: a case report. Journal of Medical Case Reports, 2013, 7, 149.	0.8	7
72	The role of continuous glucose monitoring in the care of children with type 1 diabetes. International Journal of Pediatric Endocrinology (Springer), 2013, 2013, 8.	1.6	15

#	Article	IF	CITATIONS
73	Transient Hypothyroidism in Premature Infants After Short-term Topical Iodine Exposure: An Avoidable Risk?. Pediatrics and Neonatology, 2013, 54, 128-131.	0.9	20
74	Emerging Technology in Diabetes Care: The Real-Time Diabetes Monitoring System. Military Medicine, 2013, 178, 218-221.	0.8	9
75	Extensive clinical experience: a simple guide to basal insulin adjustments for long-distance travel. Journal of Diabetes and Metabolic Disorders, 2013, 12, 59.	1.9	19
76	Characterization of the Cortisol Stress Response to Sedation and Anesthesia in Children. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1830-E1835.	3.6	34
77	Adrenal Insufficiency and Growth Failure Secondary to Inhaled Corticosteroids. Clinical Pediatrics, 2012, 51, 1194-1196.	0.8	4
78	Ganglioneuroblastoma in a young child with Turner syndrome. Journal of Pediatric Endocrinology and Metabolism, 2012, 25, 799-800.	0.9	2
79	Turner Syndrome: Updating the Paradigm of Clinical Care. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E994-E1003.	3.6	103
80	Total and Acylated Ghrelin Levels in Children With Poor Growth. Pediatric Research, 2011, 69, 517-521.	2.3	6
81	A pilot project for improving paediatric diabetes outcomes using a website: the Pediatric Diabetes Education Portal. Journal of Telemedicine and Telecare, 2011, 17, 226-230.	2.7	30
82	Ambiguous Genitalia in a Newborn with 45,X/46,X,Idic(Y) Ovotesticular Disorder of Sex Development. Endocrine Practice, 2009, 15, 732-736.	2.1	7
83	Pericardial Effusion in the Emergency Department. , 2004, 14, 212-215.		1